Clinical trials: Medication Side Effect
Carcinoid Syndrome
TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs) from baseline averaged over the 12-week…
- Trial name
- NCT01677910
- Testing
- Telotristat etiprate
- Where
- 75 sites in United States, Australia and 10 more
- Volunteers
- 135 people
- Sponsor
- Lexicon Pharmaceuticals
Heart Failure, Cardiotoxicity
The HIMALAYAS Trial and Lifestyle Changes in Pediatric, Adolescent and Young Adult Cancer Survivors Study: A Multicentre Randomized Controlled Trial
Pediatric, adolescent and young adult cancer survivors (PAYA-CS) are at higher risk of cardiovascular (CV) morbidity and mortality.
- Conditions
- Heart Failure, Cardiotoxicity, Cancer
- Trial name
- HIMALAYAS (NCT05023785)
- Testing
- Cardio-oncology Rehabilitation (CORE)
- Where
- Canada
- Volunteers
- 336 people
- Sponsor
- University Health Network, Toronto
Acetaminophen, Drug Overdose
Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose
This study is a randomized, placebo-controlled double-blinded clinical trial of patients presenting with acetaminophen poisoning who are at increased risk of developing liver injury.
- Conditions
- Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning
- Trial name
- NCT05517668
- Testing
- Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Richard Dart, MD, PhD
Graves Disease
Effective Iodide Therapy for Untreated Patients With Graves' Hyperthyroidism Avoiding Thionamide Drugs With Many Side Effects
As the drug treatment of Graves' hyperthyroidism, Plummer reported the effectiveness of excess iodide in 1923 and iodide was used as the therapy for Graves' hyperthyroidism starting from the 1930s.
- Trial name
- NCT04686006
- Testing
- Potassium Iodide
- Volunteers
- 504 people
- Sponsor
- Kyushu University
Adverse Effects, Adverse Drug Event
How Safe Are Our Pediatric Emergency Departments?
Patient safety is an internationally recognized health care priority. Canadian data suggests that about 8% of adults admitted to hospital experience unintended harm (or 'adverse events') from the health care provided during their…
- Trial name
- NCT02162147
- Where
- 10 sites in Canada
- Volunteers
- 6,385 people
- Sponsor
- Children's Hospital of Eastern Ontario
Iatrogenic Disease
Incidence of Iatrogenic Diseases on Hospital's Emergency Consultations
French population grows older year after year: 24.3% people were over 60 years old in 2006 against 20.6% in 2000 and the expected number might be over 33% in 2050.
- Trial name
- EIU (NCT03960398)
- Testing
- Iatrogenic disease impact on emergency consultations
- Where
- 2 sites in France
- Volunteers
- 2,500 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ
Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00006105
- Testing
- amifostine trihydrate, cisplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Chicago
Adverse Drug Event
Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
The rationale for this study is to evaluate the effectiveness of a risk prediction tool for patients who are at high risk for ADEs resulting in hospitalization or ED revisit.
- Trial name
- NCT04181775
- Testing
- ADE-RED scoring tool
- Where
- United States
- Volunteers
- 471 people
- Sponsor
- Methodist Health System
Self Efficacy, Drug Toxicity
High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs
the purpose of this study is to evaluate the efficacy and safety of high-dose，pulsatile Erlotinib/Gefitinib in advanced non small cell lung cancer (NSCLC) patients after failure of standard dose EGFR-TKIs（Epidermal Growth Factor…
- Trial name
- NCT01965275
- Testing
- Erlotinib or Gefitinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Anhui Medical University
Colon Cancer, Colon Diverticulosis
Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery
The General Objective of this study is to investigate the cost and efficacy of treating patients undergoing colorectal surgical resections with an opioid limited pain control regimen as part of an Enhanced Recovery After Surgery…
- Conditions
- Colon Cancer, Colon Diverticulosis, Colonic Neoplasms, Colonic Diverticulitis
- Trial name
- NCT02958566
- Testing
- Acetaminophen, Gabapentin, Orphenadrine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Illinois College of Medicine at Peoria
Lung Cancer, Head and Neck Cancer
SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
Chemotherapy treatment with platinum based agents is well noted to cause ototoxicity. It is the objective of this study to determine the safety and efficacy of SPI-1005 at three dose levels when delivered orally twice daily for 3…
- Conditions
- Lung Cancer, Head and Neck Cancer, Hearing Loss, Ototoxicity
- Trial name
- NCT01451853
- Testing
- SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose
- Where
- United States
- Sponsor
- Sound Pharmaceuticals, Incorporated
Tuberculosis, Drug Induced Liver Injury
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
To determine the efficacy of NAC to prevent clinically significant anti-TB drugs induced liver injury (AT-DILI).
- Conditions
- Tuberculosis, Drug Induced Liver Injury, Hepatitis
- Trial name
- NCT05738681
- Testing
- N acetyl cysteine
- Where
- Thailand
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Systemic Lupus Erythematosus (SLE), Juvenile SLE
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
No drug treatment is completely free of risk and lack of response, adverse events and poor adherence may affect its effectiveness.
- Conditions
- Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus
- Trial name
- NCT03122431
- Testing
- Thalidomide, Hydroxychloroquine reduced, standard dose of HCQ
- Where
- Brazil
- Volunteers
- 93 people
- Sponsor
- University of Sao Paulo General Hospital
Pregnancy, Hyperlipidemias
Bempedoic Acid Pregnancy Surveillance Program
Bempedoic acid pregnancy surveillance program
- Trial name
- NCT05103254
- Testing
- Bempedoic Acid, Bempedoic Acid / Ezetimibe
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Esperion Therapeutics, Inc.
Depression, Anxiety
Exploring Novel Uses of Microbiota Therapy for Managing the Side Effects of Psychiatric Pharmaceutical Interventions
To determine the feasibility of whether the addition of key prebiotics administered orally can mitigate some of the most problematic side-effects of the most common psychiatric medications - weight gain and metabolic…
- Trial name
- NCT05022524
- Testing
- Acetate (Apple Cider Vinegar)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Adverse Drug Reactions, Cancer
Chimeric Antigen Receptor T-cell and Cellular Therapies for the Treatment of cAncer or BLood Diseases: Evaluation of Reporting of Adverse Events
CAR-T cells and cellular therapies may lead to various adverse reactions. This study investigates reports of different toxicities for cellular therapies in the World Health Organization's (WHO) global database of individual…
- Trial name
- CARTABLE (NCT04279470)
- Testing
- CAR T-cell and Cellular Therapies
- Where
- France
- Volunteers
- 100,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Breast Cancer, Cardiotoxicity
Understanding CARdiac Events in Breast Cancer
In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime.
- Conditions
- Breast Cancer, Cardiotoxicity, Cardiomyopathies, Chemotherapeutic Toxicity
- Trial name
- UCARE (NCT05921279)
- Where
- 4 sites in Ireland
- Volunteers
- 100 people
- Sponsor
- National University of Ireland, Galway, Ireland
Adverse Mental/Physical Effects of Low Dose S. Tortuosum.
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals
Phosphodiesterase is a candidate for the Rx \& prevention of cognitive and psychotic disorders. Since caffeine targets primarily PDE4(Phosphodiesterase subtype 4), caffeine analogs have been developed to mimic the actions of…
- Trial name
- NCT01805518
- Testing
- Scelectium Tortuosum
- Where
- Puerto Rico
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Woodbury, Michel, M.D.
Drug Induced Liver Injury
Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days
Acetaminophen is commonly used to treat fever or pain. Your body clears acetaminophen by processing it in the liver. During the processing, some of the acetaminophen may bind to proteins in the liver.
- Trial name
- Non-Drinker (NCT00616018)
- Testing
- acetaminophen
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Kennon Heard
Chemotherapy-Related Cognitive Impairment, Healthy
Telerehabilitation Cognitive Impairments Following Chemotherapy Usability Study
Develop a game-based upper-extremity motor and cognitive rehabilitation system using custom and adaptable virtual reality simulations.
- Trial name
- TCIFCU (NCT04839588)
- Testing
- Usability study
- Where
- 2 sites in United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Bright Cloud International Corp